Perspectives on development and advancement of new tuberculosis vaccines
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Tuberculosis (TB) remains a leading cause of death worldwide and is estimated to have caused 1.3 million deaths worldwide in 2022. Approximately one quarter of the world's population are infected with Mycobacterium tuberculosis, of whom up to 10% will progress to developing active TB disease. Achieving the World Health Organization End TB Strategy targets of a 95% reduction in TB mortality and a 90% reduction in TB incidence worldwide by 2035 remains a daunting task. The continuing spread of multidrug-resistant TB adds another obstacle to achieving global TB control. Larger funding pledges coupled with technological advances have recently enabled the enhancement of TB vaccine development efforts. These are yielding a pipeline of over 17 products currently in different stages of clinical trials. Emerging promising phase I and II trial results and advancement to phase III trials have necessitated "vaccine preparedness" in parallel so that a smooth transition from any positive clinical trial result to phase IV evaluation and implementation into policy and practice can follow. Promotion of a human rights-based approach, which recognizes and upholds the fundamental rights of all affected by the disease, is essential to ensure universal access to quality TB vaccines, regardless of their background or personal circumstances.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141S |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 141S(2024) vom: 01. Apr., Seite 106987 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
da Costa, Christopher [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advocacy |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 18.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2024.106987 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36907534X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36907534X | ||
| 003 | DE-627 | ||
| 005 | 20240419232350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2024.106987 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM36907534X | ||
| 035 | |a (NLM)38417616 | ||
| 035 | |a (PII)S1201-9712(24)00058-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a da Costa, Christopher |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perspectives on development and advancement of new tuberculosis vaccines |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Tuberculosis (TB) remains a leading cause of death worldwide and is estimated to have caused 1.3 million deaths worldwide in 2022. Approximately one quarter of the world's population are infected with Mycobacterium tuberculosis, of whom up to 10% will progress to developing active TB disease. Achieving the World Health Organization End TB Strategy targets of a 95% reduction in TB mortality and a 90% reduction in TB incidence worldwide by 2035 remains a daunting task. The continuing spread of multidrug-resistant TB adds another obstacle to achieving global TB control. Larger funding pledges coupled with technological advances have recently enabled the enhancement of TB vaccine development efforts. These are yielding a pipeline of over 17 products currently in different stages of clinical trials. Emerging promising phase I and II trial results and advancement to phase III trials have necessitated "vaccine preparedness" in parallel so that a smooth transition from any positive clinical trial result to phase IV evaluation and implementation into policy and practice can follow. Promotion of a human rights-based approach, which recognizes and upholds the fundamental rights of all affected by the disease, is essential to ensure universal access to quality TB vaccines, regardless of their background or personal circumstances | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Advocacy | |
| 650 | 4 | |a BCG | |
| 650 | 4 | |a Immunity | |
| 650 | 4 | |a Prevention | |
| 650 | 4 | |a Tuberculosis | |
| 650 | 4 | |a Vaccines | |
| 650 | 7 | |a Tuberculosis Vaccines |2 NLM | |
| 700 | 1 | |a Benn, Christine S |e verfasserin |4 aut | |
| 700 | 1 | |a Nyirenda, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mpabalwani, Evans |e verfasserin |4 aut | |
| 700 | 1 | |a Grewal, Harleen M S |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Rizwan |e verfasserin |4 aut | |
| 700 | 1 | |a Kapata, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Nyasulu, Peter S |e verfasserin |4 aut | |
| 700 | 1 | |a Maeurer, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 700 | 1 | |a Zumla, Alimuddin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 141S(2024) vom: 01. Apr., Seite 106987 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:141S |g year:2024 |g day:01 |g month:04 |g pages:106987 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2024.106987 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141S |j 2024 |b 01 |c 04 |h 106987 | ||